{"filing":{"accession_number":"0001493152-26-038747","cik":"0001412486","ticker":"COCP","company_name":"Cocrystal Pharma, Inc.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226038747/form8-k.htm"},"events":[{"id":28271,"run_id":25849,"accession_number":"0001493152-26-038747","anchor_item_number":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Carol L. Brosgart, MD to Cocrystal Pharma's Board of Directors, effective August 12, 2026. The press release emphasizes her extensive experience in antiviral drug development, FDA approvals, and prior roles at major pharmaceutical companies (Gilead, Tobira), making this a material governance event affecting board composition and strategic direction at a clinical-stage biotech company.","company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":30156,"accession_number":"0001493152-26-038747","item_number":null,"item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Carol L. Brosgart, MD to Cocrystal Pharma's Board of Directors, effective August 12, 2026. The press release emphasizes her extensive experience in antiviral drug development, FDA approvals, and prior roles at major pharmaceutical companies (Gilead, Tobira), making this a material governance event affecting board composition and strategic direction at a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T20:20:06.348758+00:00","company_name":"Cocrystal Pharma, Inc.","ticker":"COCP","filing_date":"2026-08-17"}]}